About Obetat


Our vision

OBETAT Biopharma is, a pre-clinical stage company developing an innovative new class of potent and safe anti-obesity peptide based drug meeting unmet needs of suppressing and treating severe obesity, is seeking USA and international strategic partners interested in entering the U.S. and global markets.

Our strategy

Develop our leading compound TatdMt, a first-in-class rapid acting fat mass reducing drug, targeted for severe obesity.

We are exploring investment opportunities to complete IND enabling works, reach important development and regulatory milestones in collaboration with venture capital, pharmaceutical and biotechnology companies to develop and market products based on its core technology platform and its application to a variety of therapeutic indications.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s